CCND1 and breast cancer: The possible involvement of CCND1 and MYC as inflammasome downstream targets in BC is unknown, so the aim of our study was to elucidate the downstream signaling pathway triggered by the NLPR3 inflammasome activation in different BC molecular subtypes in order to discover novel specific potential prognostic biomarkers and identify specific subgroups of patients who could be directed to novel and more specific target therapies.